Mobile

An open-label, multicenter study to evaluate the efficacy and safety of a 4 week therapy with the single pill (SPC) combination of Aliskiren 300 mg / Amlodipine 10 mg in hypertensive patients not adeq...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-016693-33

An open-label, multicenter study to evaluate the efficacy and safety of a 4 week therapy with the single pill (SPC) combination of Aliskiren 300 mg / Amlodipine 10 mg in hypertensive patients not adequately respond to an uptitrated 4 week therapy with the SPC of Olmesartan 40 mg / Amlodipine 10 mg, with a potential extention if patients still not adequately respond with a 4 week therapy with the SPC Aliskiren 300 mg / Amlodipine 10 mg / HCTZ 12,5 mg

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To demonstrate that 4 weeks of treatment with SPC Aliskiren 300 mg / Amlodipine 10 mg at Visit 6 provide additional mean sitting diastolic blood pressure reduction in hypertensive patients not adequately responding (i.e., msDBP ≥ 90 mmHg) to 4 weeks of treatment with an Angiotensin-receptor blocker plus Amlodipine 10 mg in SPC (Olmesartan 40 mg / Amlodipine 10 mg) at Visit 5.

Critère d'inclusion

  • essential hypertension

Liens